PITX1 is a reliable biomarker for predicting prognosis in patients with oral epithelial dysplasia

Nakabayashi,Motoki; Osaki,Mitsuhiko; Kodani,Isamu; Okada,Futoshi; Ryoke,Kazuo; Oshimura,Mitsuo; Ito,Hisao; Kugoh,Hiroyuki

doi:10.3892/ol.2013.1775

PITX1 is a reliable biomarker for predicting prognosis in patients with oral epithelial dysplasia

Authors:
- Motoki Nakabayashi
- Mitsuhiko Osaki
- Isamu Kodani
- Futoshi Okada
- Kazuo Ryoke
- Mitsuo Oshimura
- Hisao Ito
- Hiroyuki Kugoh
View Affiliations

Affiliations: Division of Organ Pathology, Department of Microbiology and Pathology, Tottori University Faculty of Medicine, Tottori University Graduate School of Medical Science, Yonago, Tottori 683-8503, Japan, Division of Pathological Biochemistry, Department of Biomedical Sciences, Tottori University Faculty of Medicine, Tottori University Graduate School of Medical Science, Yonago, Tottori 683‑8503, Japan, Division of Oral and Maxillofacial Biopathological Surgery, Department of Sensory and Motor Organ Medicine, Tottori University Faculty of Medicine, Tottori University Graduate School of Medical Science, Yonago, Tottori 683-8503, Japan, Division of Molecular Genetics and Biofunction, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, Yonago, Tottori 683‑8503, Japan
Published online on: December 24, 2013 https://doi.org/10.3892/ol.2013.1775
Pages: 750-754

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paired‑like homeodomain 1 (PITX1) genes are essential in human development. In the present study, PITX1 protein expression was evaluated in human normal oral mucosa, oral epithelial dysplasia and oral squamous cell carcinoma (OSCC), with the aim of examining the expression patterns of these critical genes during the multi‑stage transformation of oral epithelial dysplasia to OSCC. PITX1 and Ki‑67 expression were assessed by immunohistochemistry in 26 individuals with normal oral mucosa, 106 patients with oral epithelial dysplasia and 97 OSCC patients. The labeling indices (LIs) of PITX1 and Ki‑67 were calculated and their correlation with the incidence of malignancy was evaluated. The PITX1 LI of the dysplasia specimens was significantly lower than that of the normal oral mucosa samples, but significantly higher than that of the OSCC samples. The oral epithelial dysplasia patients that exhibited low PITX1 expression showed a significantly higher incidence of malignant transformation than those exhibiting high PITX1 expression, regardless of the histological grades of their oral epithelial dysplasias. On the other hand, no correlation was observed between the Ki‑67 LI and the incidence of malignancy. These results suggested that PITX1 suppression is associated with malignant transformation in the oral epithelium and that PITX1 expression may serve as a novel biomarker for predicting prognosis in oral epithelial dysplasia.

View Figures

View References

1	Bánóczy J and Csiba A: Occurrence of epithelial dysplasia in oral leukoplakia. Analysis and follow-up study of 12 cases. Oral Surg Oral Med Oral Pathol. 42:766–774. 1976.
2	van der Waal I: Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 45:317–323. 2009.
3	Gupta PC, Mehta FS, Daftary DK, et al: Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol. 8:283–333. 1980.PubMed/NCBI
4	Silverman S Jr, Gorsky M and Lozada F: Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 53:563–568. 1984. View Article : Google Scholar : PubMed/NCBI
5	Bouquot JE and Whitaker SB: Oral leukoplakia - rationale for diagnosis and prognosis of its clinical subtypes or ‘phases’. Quintessence Int. 25:133–140. 1994.PubMed/NCBI
6	Napier SS and Speight PM: Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med. 37:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
7	Piemonte ED, Lazos JP and Brunotto M: Relationship between chronic trauma of the oral mucosa, oral potentially malignant disorders and oral cancer. J Oral Pathol Med. 39:513–517. 2010.PubMed/NCBI
8	Reibel J: Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 14:47–62. 2003. View Article : Google Scholar
9	Imoto I, Pimkhaokham A, Watanabe T, et al: Amplification and overexpression of TGIF2, a novel homeobox gene of the TALE superclass, in ovarian cancer cell lines. Biochem Biophys Res Commun. 276:264–270. 2000. View Article : Google Scholar : PubMed/NCBI
10	Lamonerie T, Tremblay JJ, Lanctôt C, et al: Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev. 10:1284–1295. 1996. View Article : Google Scholar : PubMed/NCBI
11	DeLaurier A, Schweitzer R and Logan M: Pitx1 determines the morphology of muscle, tendon, and bones of the hindlimb. Dev Biol. 299:22–34. 2006. View Article : Google Scholar : PubMed/NCBI
12	Shang J, Li X, Ring HZ, et al: Backfoot, a novel homeobox gene, maps to human chromosome 5 (BFT) and mouse chromosome 13 (Bft). Genomics. 40:108–113. 1997. View Article : Google Scholar : PubMed/NCBI
13	Lanctôt C, Moreau A, Chamberland M, et al: Hindlimb patterning and mandible development require the Ptx1 gene. Development. 126:1805–1810. 1999.PubMed/NCBI
14	Shang J, Luo Y and Clayton DA: Backfoot is a novel homeobox gene expressed in the mesenchyme of developing hindlimb. Dev Dyn. 209:242–253. 1997. View Article : Google Scholar : PubMed/NCBI
15	Libório TN, Acquafreda T, Matizonkas-Antonio LF, et al: In situ hybridization detection of homeobox genes reveals distinct expression patterns in oral squamous cell carcinomas. Histopathology. 58:225–233. 2011.PubMed/NCBI
16	Lord RV, Brabender J, Wickramasinghe K, et al: Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett’s esophagus and Barrett’s-associated adenocarcinoma. Surgery. 138:924–931. 2005.PubMed/NCBI
17	Chen YN, Chen H, Xu Y, et al: Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance. World J Gastroenterol. 14:292–297. 2008. View Article : Google Scholar : PubMed/NCBI
18	Qi DL, Ohhira T, Fujisaki C, et al: Identification of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol Cell Biol. 31:1624–1636. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chen Y, Knösel T, Ye F, et al: Decreased PITX1 homeobox gene expression in human lung cancer. Lung Cancer. 55:287–294. 2007. View Article : Google Scholar : PubMed/NCBI
20	Stender JD, Stossi F, Funk CC, et al: The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells. Mol Endocrinol. 25:1699–1709. 2011. View Article : Google Scholar
21	Calvisi DF, Ladu S, Conner EA, et al: Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 54:311–319. 2011. View Article : Google Scholar
22	Knösel T, Chen Y, Hotovy S, et al: Loss of desmocollin 1–3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. Int J Colorectal Dis. 27:1391–1399. 2012.
23	Hamidov Z, Altendorf-Hofmann A, Chen Y, et al: Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma. J Clin Pathol. 64:990–994. 2011. View Article : Google Scholar
24	Kwok SC, Liu X, Mangel P and Daskal I: PTX1(ERGIC2)-VP22 fusion protein upregulates interferon-beta in prostate cancer cell line PC-3. DNA Cell Biol. 25:523–529. 2006. View Article : Google Scholar : PubMed/NCBI
25	Osaki M, Chinen H, Yoshida Y, et al: Decreased PITX1 gene expression in human cutaneous malignant melanoma and its clinicopathological significance. Eur J Dermatol. Jun 28–2013.(Epub ahead of print).
26	Pindborg JJ, Smith CJ and van der Waal I: Histological typing of cancer and precancer of the oral mucosa (2nd edition), World Health Organization. Springer-Verlag; Berlin: pp. 24–40. 1997
27	Kodani I, Shomori K, Osaki M, et al: Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa. Pathobiology. 69:150–158. 2001. View Article : Google Scholar
28	Gouvêa AF, Vargas PA, Coletta RD, et al: Clinicopathological features and immunohistochemical expression of p53, Ki-67, Mcm-2 and Mcm-5 in proliferative verrucous leukoplakia. J Oral Pathol Med. 39:447–452. 2010.PubMed/NCBI
29	Nasser W, Flechtenmacher C, Holzinger D, et al: Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med. 40:629–635. 2011. View Article : Google Scholar : PubMed/NCBI
30	Nogami T, Kuyama K and Yamamoto H: Histopathological and immunohistochemical study of malignant transformation of oral leukoplakia, with special reference to apoptosis-related gene products and proliferative activity. Acta Otolaryngol. 123:767–775. 2003.
31	Matsubara R, Kuwano S, Kiyosue T, et al: Increased ΔNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma. Int J Oncol. 39:1391–1399. 2011.
32	Thomson PJ, Soames JV, Booth C and O’Shea JA: Epithelial cell proliferative activity and oral cancer progression. Cell Prolif. 35(Suppl 1): S110–S120. 2002. View Article : Google Scholar
33	Kumar P, Kane S and Rathod GP: Coexpression of p53 and Ki 67 and lack of c-erbB2 expression in oral leukoplakias in India. Braz Oral Res. 26:228–234. 2012. View Article : Google Scholar : PubMed/NCBI
34	Iamaroon A, Khemaleelakul U, Pongsiriwet S and Pintong J: Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med. 33:30–36. 2004. View Article : Google Scholar : PubMed/NCBI
35	Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
36	Oliveira LR and Ribeiro-Silva A: Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 40:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
37	Kolfschoten IG, van Leeuwen B, Berns K, et al: A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 121:849–858. 2005. View Article : Google Scholar : PubMed/NCBI